These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 34780081)

  • 1. Changes in therapeutic options for hepatocellular carcinoma in Asia.
    Ogasawara S; Koroki K; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Kato N
    Liver Int; 2022 Aug; 42(9):2055-2066. PubMed ID: 34780081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
    Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
    Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
    Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
    JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indonesian consensus on systemic therapies for hepatocellular carcinoma.
    Hasan I; Loho IM; Setiawan PB; Djumhana A; Purnomo HD; Siregar L; Gani RA; Sulaiman AS; Lesmana CRA
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):263-274. PubMed ID: 35599455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment options for hepatocellular carcinoma.
    Eugen K
    Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapies for hepatocellular carcinoma: the present and the future.
    Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G
    Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment for hepatocellular carcinoma.
    Ján T; Dáša S; Igor A; Jana V
    Klin Onkol; 2020; 33(5):356-361. PubMed ID: 33108880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
    Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
    Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
    Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
    Ghaziani TT; Dhanasekaran R
    Curr Treat Options Gastroenterol; 2021 Jun; 19(2):351-368. PubMed ID: 35530750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.